A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
Abstract Background Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, ana...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2020-08-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13550-020-00677-3 |
| _version_ | 1811337883427012608 |
|---|---|
| author | Rosalba Mansi Karim Abid Guillaume P. Nicolas Luigi Del Pozzo Eric Grouzmann Melpomeni Fani |
| author_facet | Rosalba Mansi Karim Abid Guillaume P. Nicolas Luigi Del Pozzo Eric Grouzmann Melpomeni Fani |
| author_sort | Rosalba Mansi |
| collection | DOAJ |
| description | Abstract Background Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, analogs targeting more subtypes than SST2 potentially target a broader spectrum of tumors and/or increase the uptake of a given tumor. The analog ST8950 ((4-amino-3-iodo)-d-Phe-c[Cys-(3-iodo)-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2), bearing 2 iodo-amino acids, exhibits sub-nanomolar affinity to SST2 and SST5. We report herein the development and preclinical evaluation of DOTA-ST8950 labeled with 68Ga, for imaging SST2- and SST5-expressing tumors. Comparative in vitro and in vivo studies were performed with the de-iodinated DOTA-ST8951 ((4-amino)-d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2) and with the reference compounds DOTA-TATE (SST2 selective) and DOTA-NOC (for SST2 and SST5). Results Compared with natGa-DOTA-NOC, natGa-DOTA-ST8950 exhibited higher affinity to SST2 and SST5 (IC50 (95%CI), nM = 0.32 (0.20–0.50) and 1.9 (1.1–3.1) vs 0.70 (0.50-0.96) and 3.4 (1.8-6.2), respectively), while natGa-DOTA-ST8951 lost affinity for both subtypes. natGa-DOTA-ST8950 had the same potency for inducing SST2-mediated cAMP accumulation as natGa-DOTA-TATE and slightly better than natGa-DOTA-NOC (EC50, nM = 0.46 (0.23–0.92) vs 0.47 (0.15–1.5) vs 0.59 (0.18–1.9), respectively). [67Ga]Ga-DOTA-ST8950 had a similar internalization rate as [67Ga]Ga-DOTA-NOC in SST2-expressing cells (12.4 ± 1.6% vs 16.6 ± 2.2%, at 4 h, p = 0.0586). In vivo, [68Ga]Ga-DOTA-ST8950 showed high and specific accumulation in SST2- and SST5-expressing tumors, comparable with [68Ga]Ga-DOTA-NOC (26 ± 8 vs 30 ± 8 %IA/g, p = 0.4630 for SST2 and 15 ± 6 vs 12 ± 5 %IA/g, p = 0.3282, for SST5, 1 h p.i.) and accumulation in the SST-positive tissues, the kidneys and the liver. PET/CT images of [68Ga]Ga-DOTA-ST8950, performed in a dual HEK-SST2 and HEK-SST5 tumor xenografted model, clearly visualized both tumors and illustrated high tumor-to-background contrast. Conclusions [68Ga]Ga-DOTA-ST8950 reveals its potential for PET imaging SST2- and SST5-expressing tumors. It compares favorably with the clinically used [68Ga]Ga-DOTA-NOC in terms of tumor uptake; however, its uptake in the liver remains a challenge for clinical translation. In addition, this study reveals the essential role of the iodo-substitutions in positions 1 and 3 of [68Ga]Ga-DOTA-ST8950 for maintaining affinity to SST2 and SST5, as the de-iodinated [68Ga]Ga-DOTA-ST8951 lost affinity for both receptor subtypes. |
| first_indexed | 2024-04-13T18:01:35Z |
| format | Article |
| id | doaj.art-4dc9844c52274a5393ea58285478f33d |
| institution | Directory Open Access Journal |
| issn | 2191-219X |
| language | English |
| last_indexed | 2024-04-13T18:01:35Z |
| publishDate | 2020-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj.art-4dc9844c52274a5393ea58285478f33d2022-12-22T02:36:13ZengSpringerOpenEJNMMI Research2191-219X2020-08-0110111010.1186/s13550-020-00677-3A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targetingRosalba Mansi0Karim Abid1Guillaume P. Nicolas2Luigi Del Pozzo3Eric Grouzmann4Melpomeni Fani5Division of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital BaselCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of LausanneDivision of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital BaselDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital BaselCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of LausanneDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital BaselAbstract Background Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, analogs targeting more subtypes than SST2 potentially target a broader spectrum of tumors and/or increase the uptake of a given tumor. The analog ST8950 ((4-amino-3-iodo)-d-Phe-c[Cys-(3-iodo)-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2), bearing 2 iodo-amino acids, exhibits sub-nanomolar affinity to SST2 and SST5. We report herein the development and preclinical evaluation of DOTA-ST8950 labeled with 68Ga, for imaging SST2- and SST5-expressing tumors. Comparative in vitro and in vivo studies were performed with the de-iodinated DOTA-ST8951 ((4-amino)-d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2) and with the reference compounds DOTA-TATE (SST2 selective) and DOTA-NOC (for SST2 and SST5). Results Compared with natGa-DOTA-NOC, natGa-DOTA-ST8950 exhibited higher affinity to SST2 and SST5 (IC50 (95%CI), nM = 0.32 (0.20–0.50) and 1.9 (1.1–3.1) vs 0.70 (0.50-0.96) and 3.4 (1.8-6.2), respectively), while natGa-DOTA-ST8951 lost affinity for both subtypes. natGa-DOTA-ST8950 had the same potency for inducing SST2-mediated cAMP accumulation as natGa-DOTA-TATE and slightly better than natGa-DOTA-NOC (EC50, nM = 0.46 (0.23–0.92) vs 0.47 (0.15–1.5) vs 0.59 (0.18–1.9), respectively). [67Ga]Ga-DOTA-ST8950 had a similar internalization rate as [67Ga]Ga-DOTA-NOC in SST2-expressing cells (12.4 ± 1.6% vs 16.6 ± 2.2%, at 4 h, p = 0.0586). In vivo, [68Ga]Ga-DOTA-ST8950 showed high and specific accumulation in SST2- and SST5-expressing tumors, comparable with [68Ga]Ga-DOTA-NOC (26 ± 8 vs 30 ± 8 %IA/g, p = 0.4630 for SST2 and 15 ± 6 vs 12 ± 5 %IA/g, p = 0.3282, for SST5, 1 h p.i.) and accumulation in the SST-positive tissues, the kidneys and the liver. PET/CT images of [68Ga]Ga-DOTA-ST8950, performed in a dual HEK-SST2 and HEK-SST5 tumor xenografted model, clearly visualized both tumors and illustrated high tumor-to-background contrast. Conclusions [68Ga]Ga-DOTA-ST8950 reveals its potential for PET imaging SST2- and SST5-expressing tumors. It compares favorably with the clinically used [68Ga]Ga-DOTA-NOC in terms of tumor uptake; however, its uptake in the liver remains a challenge for clinical translation. In addition, this study reveals the essential role of the iodo-substitutions in positions 1 and 3 of [68Ga]Ga-DOTA-ST8950 for maintaining affinity to SST2 and SST5, as the de-iodinated [68Ga]Ga-DOTA-ST8951 lost affinity for both receptor subtypes.http://link.springer.com/article/10.1186/s13550-020-00677-3Somatostatin receptor subtypesSomatostatin agonistsSST2SST568GaPET |
| spellingShingle | Rosalba Mansi Karim Abid Guillaume P. Nicolas Luigi Del Pozzo Eric Grouzmann Melpomeni Fani A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting EJNMMI Research Somatostatin receptor subtypes Somatostatin agonists SST2 SST5 68Ga PET |
| title | A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| title_full | A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| title_fullStr | A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| title_full_unstemmed | A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| title_short | A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| title_sort | new 68ga labeled somatostatin analog containing two iodo amino acids for dual somatostatin receptor subtype 2 and 5 targeting |
| topic | Somatostatin receptor subtypes Somatostatin agonists SST2 SST5 68Ga PET |
| url | http://link.springer.com/article/10.1186/s13550-020-00677-3 |
| work_keys_str_mv | AT rosalbamansi anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT karimabid anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT guillaumepnicolas anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT luigidelpozzo anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT ericgrouzmann anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT melpomenifani anew68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT rosalbamansi new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT karimabid new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT guillaumepnicolas new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT luigidelpozzo new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT ericgrouzmann new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting AT melpomenifani new68galabeledsomatostatinanalogcontainingtwoiodoaminoacidsfordualsomatostatinreceptorsubtype2and5targeting |